Quadria Capital Plans Major Exits via Maxivision and Aragen IPOs by 2027
Healthcare-focused private equity firm Quadria Capital is targeting 1.5x cash returns for its investors by early 2027. The firm plans to achieve this through public listings of portfolio companies like Maxivision Eye Hospital and Aragen Life Sciences.
Key takeaways
- Quadria Capital aims to return 1.5 times the invested cash to its Fund III backers by early 2027.
- The exit strategy heavily relies on the upcoming IPOs of Maxivision Eye Hospital and Aragen Life Sciences.
- The firm is capitalizing on high liquidity and favorable valuations in the Indian healthcare market.
- Retail investors should watch for these upcoming healthcare IPOs as potential portfolio additions.
Healthcare-focused private equity firm Quadria Capital is targeting 1.5x cash returns for its investors by early 2027. The firm plans to achieve this through public listings of portfolio companies like Maxivision Eye Hospital and Aragen Life Sciences.
Quadria Capital, a leading healthcare-focused private equity firm, has announced an aggressive exit strategy aimed at delivering significant returns to its backers. The firm is targeting a 1.5x cash return from its third fund (Fund III) by early 2027, leveraging the current high liquidity in the Indian capital markets.
IPO Pipeline: Maxivision and Aragen
The cornerstone of this exit strategy involves the public listing of two major portfolio companies: Maxivision Eye Hospital and Aragen Life Sciences. According to Amit Varma, co-founder and managing partner of Quadria Capital, these Initial Public Offerings (IPOs) are timed to tap into the strong domestic appetite for healthcare and pharmaceutical stocks.
- Maxivision Eye Hospital: A leading eye care chain in India, expected to seek a public listing to fund further expansion and provide an exit route for early investors.
- Aragen Life Sciences: A major contract research, development, and manufacturing organization (CRDMO) that serves the global pharmaceutical and biotech industries.
Strategic Shift to Cash Returns
The move signals a shift from capital deployment to capital return. While Quadria continues to scout for new opportunities in the South Asian healthcare sector, the immediate priority for Fund III is to crystallize gains. The firm believes that the Indian market's current valuation premiums for healthcare services make it an opportune time for exits.
What This Means for the Healthcare Sector
The planned IPOs of Maxivision and Aragen are expected to add significant depth to the healthcare segment of the Indian stock exchanges. For retail investors, these upcoming listings represent new opportunities to gain exposure to specialized healthcare services and pharmaceutical research sectors, which have shown resilience and growth post-pandemic.
Quadria’s confidence in achieving a 1.5x return within the next three years underscores the robust growth trajectory of private-equity-backed healthcare firms in India. As these companies transition from private to public ownership, they are likely to face increased scrutiny regarding corporate governance and long-term profitability.
This report is for informational purposes only and does not constitute financial or investment advice.
Frequently asked questions
Which companies is Quadria Capital planning to list on the stock exchange?
Quadria Capital is planning public listings for Maxivision Eye Hospital and Aragen Life Sciences.
What is the timeline for Quadria Capital's planned exits?
The firm aims to complete these exits and provide returns to investors by early 2027.
Why is Quadria Capital choosing to exit now?
The firm is leveraging strong domestic market liquidity and high demand for healthcare stocks in India to maximize returns.